Abbott Laboratories (ABT) shares are trading around $112, reflecting a 16% pullback from recent highs due to a FreeStyle Libre 3 sensor recall and weakness in the Nutrition segment. Despite these headwinds, the company’s Medical Devices segment remains strong, and upcoming catalysts including the Exact Sciences acquisition and the Volt PFA launch have analysts projecting a mean price target of $133.39.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Abbott Laboratories Stock Is Down 16% From Its 52-Week High. Here’s Where the Stock Could Go in 2026
Abbott Laboratories (ABT) shares are trading around $112, reflecting a 16% pullback from recent highs due to a FreeStyle Libre 3 sensor recall and weakness in the Nutrition segment. Despite these headwinds, the company’s Medical Devices segment remains strong, and upcoming catalysts including the Exact Sciences acquisition and the Volt PFA launch have analysts projecting a mean price target of $133.39.